Loading clinical trials...

HIV Counseling Intervention for Methadone-Maintained Patients - 2 | Clinical Trials | Clareo Health

COMPLETEDPHASE1

HIV Counseling Intervention for Methadone-Maintained Patients - 2

HIV Counseling Intervention for Methadone-Maintained Patients

NCT00061100•New York State Psychiatric Institute

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate HIV counseling intervention for Methadone-Maintained Patients.

Detailed Description

The purpose of this proposal is to evaluate, in methadone-maintained patients the association between an ADHD diagnosis and high-risk HIV/Hepatitis behavior. In addition, the investigators would like to determine whether a new manually-guided HIV intervention; RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounters is superior to standard HIV/Hepatitis psycho-education.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must meet DSM-IV criteria for opiate dependence and currently in methadone maintenance treatment
•Able to give informed consent and capable of complying with study procedures
•Women who are of childbearing age and/or pregnant may be included
•Individuals who are HIV-positive or have Acquired Immunodeficiency Syndrome may be included
•Patients who demonstrate moderate to high HIV risk behaviors will be included
•Patients with low to no HIV risk behaviors will be excluded
•Patients receiving a stable dose of methadone for three weeks will be included

Exclusion Criteria

•Currently meets DSM-IV criteria for current Axis I psychiatric disorders (other than ADHD or substance abuse) which requires medical intervention, i.e., active suicide ideation, active psychosis, anxiety disorders, depression requiring hospitalization
•Patients who have exhibited suicidal or homicidal behavior within the past two years
•HIV positive patients must have knowledge of their status for a minimum of three weeks

Locations (1)

Research Foundation for Mental Hygiene, Inc.

New York, New York, United States

Key Dates

Start Date

October 1, 1999

Primary Completion Date

October 1, 2003

Completion Date

October 1, 2003

Last Updated

April 23, 2019

Enrollment

ACTUAL participants

Conditions

Opioid-Related Disorders

Interventions

Behavior Therapy-RISE

BEHAVIORAL

Standard prevention Education

BEHAVIORAL

Tau PET Imaging in Opioid Use Disorder

NCT05651516

Opioid-Related Disorders

View study

ACTIVE_NOT_RECRUITINGNA

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

NCT05505227

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 23, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

HIV Counseling Intervention for Methadone-Maintained Patients - 2

Inclusion Criteria

Exclusion Criteria

Tau PET Imaging in Opioid Use Disorder

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Erector Spinae Plane Block Versus Serratus Anterior Plane Block

Social Work Assistance and Stipends for Housing (SASH)